Eli Lilly and Co banner

Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 1 054.3 USD 3.28% Market Closed
Market Cap: $996.7B

Relative Value

The Relative Value of one LLY stock under the Base Case scenario is hidden USD. Compared to the current market price of 1 054.3 USD, Eli Lilly and Co is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LLY Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

LLY Competitors Multiples
Eli Lilly and Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eli Lilly and Co
NYSE:LLY
997.2B USD 15.3 48.3 32.5 34.6
US
Johnson & Johnson
NYSE:JNJ
578.6B USD 6.1 21.6 15 18.4
CH
Roche Holding AG
SIX:ROG
281.1B CHF 4.6 30 12.7 14.8
US
Merck & Co Inc
NYSE:MRK
303.5B USD 4.7 16.6 10.4 12.1
CH
Novartis AG
SIX:NOVN
230.9B CHF 5.3 21.2 13.1 16.8
UK
AstraZeneca PLC
LSE:AZN
216.1B GBP 5.2 32.1 15.3 22.4
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.7 9.3 11
US
Pfizer Inc
NYSE:PFE
154.7B USD 2.5 19.9 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
125.6B USD 2.6 20.8 7.3 9.6
UK
GlaxoSmithKline PLC
LSE:GSK
88.8B GBP 2.7 15.6 7.9 11.2
P/E Multiple
Earnings Growth PEG
US
Eli Lilly and Co
NYSE:LLY
Average P/E: 23.9
48.3
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.6
7%
3.1
CH
Roche Holding AG
SIX:ROG
30
29%
1
US
Merck & Co Inc
NYSE:MRK
16.6
14%
1.2
CH
Novartis AG
SIX:NOVN
21.2
15%
1.4
UK
AstraZeneca PLC
LSE:AZN
32.1
38%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
7%
1.8
US
Pfizer Inc
NYSE:PFE
19.9
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
20.8
N/A N/A
UK
GlaxoSmithKline PLC
LSE:GSK
15.6
18%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBITDA: 42.2
32.5
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
US
Merck & Co Inc
NYSE:MRK
10.4
7%
1.5
CH
Novartis AG
SIX:NOVN
13.1
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
15.3
10%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
7%
1.3
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-9%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
7.9
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBIT: 90.6
34.6
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.4
6%
3.1
CH
Roche Holding AG
SIX:ROG
14.8
6%
2.5
US
Merck & Co Inc
NYSE:MRK
12.1
6%
2
CH
Novartis AG
SIX:NOVN
16.8
12%
1.4
UK
AstraZeneca PLC
LSE:AZN
22.4
23%
1
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11
8%
1.4
US
Pfizer Inc
NYSE:PFE
9.9
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.6
10%
1
UK
GlaxoSmithKline PLC
LSE:GSK
11.2
12%
0.9